Journals / Klinik Psikofarmakoloji Bülteni / 2006 / Cilt: 16 - Sayı: 1

What is chronic fatigue immune dysfunction syndrome?

Kronik yorgunluk immün disfonksiyon sendromu nedir ?

Pages
63–76
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The assessment and management of CFIDS patient should be multidimensional and psychiatrist should be a pervasive member of the multidisciplinary team for CFIDS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic fatigue immune dysfunction syndrome (CFIDS) is a central nervous system dysfunction characterized by profound disabling fatigue of at least 6 months and accompanied by multisystemic involvement manifesting itself with neuropsychiatric, neuroendocrinologic and immunologic symptoms.
📊
Key Findings & Data:Patients with CFIDS experience profound functional impairment resulting in a significant decrease in their quality of life.
💡
Conclusion & Impact:The assessment and management of CFIDS patient should be multidimensional and psychiatrist should be a pervasive member of the multidisciplinary team for CFIDS.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Chronic fatigue immune dysfunction syndrome (CFIDS) is a central nervous system dysfunction characterized by profound disabling fatigue of at least 6 months and accompanied by multisystemic involvement manifesting itself with neuropsychiatric, neuroendocrinologic and immunologic symptoms. This review summarizes the current knowledge about CFIDS, which is little known in Turkish medical literature. Case definition, clinical presentation, evaluation, treatment and pathogenetic theories of CFIDS will be discussed in the light of the relevant literature. CFIDS is diagnosed on the basis of the clinically defined criteria. Patients with CFIDS experience profound functional impairment resulting in a significant decrease in their quality of life. Several research findings suggest that CFIDS is one of the stress-mediated disorders and should be distinct from psychiatric disorders. Existing pathophysiological abnormalities suggest that CFIDS is a heterogeneous condition of complex multifactorial etiology. Accumulating evidence also considers that dysfunction of HPA axis and serotonergic pathways in central nervous system may play an important role in the pathogenesis of CFIDS. Treatment for CFIDS is not specific but symptom-based and aimed at decreasing the level of stress. Graded exercise and cognitive behavioral therapy may be effective in increasing fitness and learning to cope with this disabling catastrophic syndrome, respectively. It has been reported that some experimental agents may be beneficial for treatment of some CFIDS patients. CFIDS is unlikely to be caused by a single agent. The data indicate that many environmental or psychological factors may precipitate or perpetuate the illness in genetically vulnerable subjects. The assessment and management of CFIDS patient should be multidimensional and psychiatrist should be a pervasive member of the multidisciplinary team for CFIDS.

Özet

Kronik yorgunluk immün disfonksiyon sendromu (CFIDS) nöropsikiyatrik, nöroendokrinolojik, immünolojik semptomlarla kendini gösteren multisistemik tutulumlu, 6 aydan fazla süreli sakatlayıcı ve ağır bitkinlik ile karakterize bir santral sinir sistemi işlev bozukluğudur. Bu gözden geçirme yazısı Türkçe tıbbi literatürde pek az yer alan CFIDS hakkı ndaki güncel bilgileri özetlemektedir. CFIDS’in klinik tanımlaması, değerlendirmesi, tedavisi ve patogenetik teorileri ilgili literatürün ışığında tartışılacaktır. CFIDS klinik kriterlere dayalı olarak teşhis edilir. CFIDS hastaları hayat kalitelerinde önemli bir azalma ile sonuçlanan ağır bir işlevsel bozulma yaşarlar. Birçok çalışmanın bulgularına dayanılarak, CFIDS’in stresin aracılık ettiği bozukluklar sınıfına dahil bir sendrom olduğu ve psikiyatrik bozukluklardan ayırılması gerektiği ileri sürülmektedir. Mevcut patofizyolojik anormallikler CFIDS’in kompleks ve multifaktoriyel etyolojili heterojen bir durum olduğunu düşündürmektedir. Biriken deliller de santral sinir sisteminde HPA eksenin ve serotonin yolaklarının işlev bozukluğunun CFIDS patogenezinde önemli rol oynayabileceğini akla getirmektedir. CFIDS tedavisi özgün olmayıp semptomlara ve stres düzeyini düşürmeye yöneliktir. Tedricen artırılan egzersizin fiziksel kondisyonu iyileştirmede, bilişsel davranışçı tedavinin ise bu sakatlayı cı katastrofik sendromla başa çıkmayı öğrenmede etkili olabileceği düşünülmektedir. Deneysel tedavilerin bazı CFIDS hastaları için faydalı olabileceği de bildirilmektedir. CFIDS tek bir sebebe bağlı gibi görünmemektedir. Veriler genetik bakı mdan yatkınlığı olan şahıslarda birçok çevresel ve psikolojik faktörün sendromu başlatabileceğini veya şiddetlendirebileceğini göstermektedir. CFIDS hastasının değerlendirilmesi yanında tedavisi de çok boyutlu olarak yapılmalıdır ve psikiyatrist CFIDS multidisipliner ekibinin daimi bir üyesi olmalıdır

🔖

Cite This Article

ASDEMİR, A., SOFUOĞLU, S., İZGİ, H. B. (2022). What is chronic fatigue immune dysfunction syndrome?. Klinik Psikofarmakoloji Bülteni, Cilt: 16 - Sayı: 1, 63–76. https://ajindex.com/articles/574407

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A, and the International Study Group. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994
  2. 959 2. Buchwald D, Ashley RL, Pearlman T, Kith P, Komaroff AL. Viral serologies in patients with chronic fatigue and chronic fatigue syndrome. J Med Virol 1996
  3. 30 3. Fidaner H. Kronik yorgunluk sendromu. Klinik Psikiyatri Dergisi 1999
  4. 265 4. Sofuoğlu S, Gönül AS. Kronik Yorgunluk Sendromu veya Canlı Cenaze Sendromu. Servier İlaç Araştırma A.Ş. istanbul: 5G Matbaacılık, 2001 5. Bozdemir N, Sofuoğlu S. Kronik yorgunluk sendromu: Derleme. Klinik Psikiyatri 2001
  5. 59 6. Briggs NC, Levine PH. A comparative review of systemic and neurological symptomatology in 12 outbreaks collectively described as chronic fatigue syndrome, epidemic neuromyasthenia and myalgic encephalomyelitis. Clin Infect Dis 1994
  6. 18 (Suppl.1):32-42 7. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003
  7. 236 8. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lemer AM, Bested AC, Henry PF, Joshi P, Powles ACP, Sherkey JA, van de Sande Ml. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: clinical working case definition, diagnostic and treatment protocols (a consensus document): Journal of Chronic Fatigue Syndrome: Multidiciplinary Innovations in Research, Theory & Clinical Practice 2003
  8. 115 9. Euba R, Chalder T, Deale A, Wessely S. A comparison of the characteristics of chronic fatigue syndrome in primary and tertiary care. Br J Psychiatry 1996
  9. 126 10. Gur A, Çevik R, Nas K, Çolpan L, Saraç S. Cortisol and hypothalamic-pituitary-gonadal axis hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones. Arthritis Res Ther 2004
  10. 238 11. Nicolson GL, Nasrallah MY, Nicolson NL. High prevalence of mycoplasma infections in symptomatic (chronic fatigue syndrome) family members of mycoplasma-positive Gulf War illness patients. Journal of Chronic Fatigue Syndrome 2003
  11. 36 12. Cleare AJ. The HPA axis and the genesis of chronic fatigue syndrome. Trends Endocrinol Metab 2004
  12. 59 13. Bell DS. The Doctor's Guide to Chronic Fatigue Syndrome: Understanding, Treating and Living with CFIDS. Da Capo Press (a member of the Perseus Books Group) US 1995 pp:7-18, 25-42 14. Taylor RR, Jgson LA, Richman JA, Torres-Harding SR, King C, Song S